BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//InBio - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:InBio
X-ORIGINAL-URL:https://inbio.com
X-WR-CALDESC:Events for InBio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220226
DTEND;VALUE=DATE:20220301
DTSTAMP:20260601T230745
CREATED:20221108T151132Z
LAST-MODIFIED:20221108T151350Z
UID:535-1645833600-1646092799@inbio.com
SUMMARY:InBio Attending AAAAI Annual Meeting 2022
DESCRIPTION:InBio Attending 2022 AAAAI \nInBio is excited to kick-off the year by attending our first big conference\, the American Academy of Allergy\, Asthma and Immunology Annual Meeting\, starting February 26th. The AAAAI Annual Meeting is always one of the highlights of the year. \nInBio will be presenting five oral abstracts and posters\, covering such diverse topics as T cell immune responses to SARS-CoV-2 vaccines\, human IgE monoclonal antibodies\, allergen levels in baked foods\, cannabis allergen\, and CRISPR for cats. \nIn other news\, InBio is delighted to announce that Dr. Anna Pomés\, Director of Research\, is the recipient of the Harold S. Nelson MD\, FAAAI Lectureship: Investing Together in Our Future. This award will be presented prior to Anna’s lecture on “Human Monoclonal IgE Antibodies to Allergens” at the National Institute of Environmental Health Sciences AAAAI Symposium 2522 on Saturday\, Feb 26th at 12:30pm MST. Congratulations to Anna on this outstanding achievement\, which is thoroughly deserved and represents peer recognition of Anna’s NIH funded research over the past 15 years. \nPlease find details of InBio’s presence at the AAAAI meeting below. InBio will be at Booth 1018 as well as on the virtual platform with exciting announcements and a new look. Hope to see you there! \nIndoor Biotechnologies scientists will be presenting five oral presentations and posters in person and virtually\, including an AAAAI Foundation and Harold S. Nelson\, MD FAAAAI Lectureship by Dr. Anna Pomés\, “Human Monoclonal IgE Antibodies to Allergens.” Find details on InBio’s 2022 AAAAI content below. \nSaturday\, February 26th\, 2022\nAAAAI Foundation and Harold S. Nelson\, MD FAAAAI Lectureship: Investing Together in Our Future (3rd year)- Human Monoclonal IgE Antibodies to Allergens\nLecturer: Anna Pomés\, PhD FAAAAI\nSession: 2522 National Institute of Environmental Health Sciences (NIEHS): Molecular Characterization of Allergens and Specific IgE Antibodies\nLocation: Convention Center\, North Building\, 100 Level\, Room 120D\nDate/Time: Saturday\, February 26th at 12:55 PM \nAbstract Title: Interleukin-2: An Accurate Biomarker for Rapid Testing of SARS-CoV-2 Vaccine-induced T cell Immune Responses in Whole Blood\nPresenter: Maria Oliver\, PhD\nSession: Caring for Patients with Immunodeficiency Disorders During the COVID-19 Pandemic\nLocation: Convention Center\, West Building\, 300 Level\, Room 301C\nDate/Time: Saturday\, February 26th at 2:35 PM \nSunday\, February 27\, 2022\nPoster presentation: Significant Reduction of Specific Allergen Levels in Baked Egg Foods\nPresenter: Stephanie Filep\nLocation: Convention Center\, North Building\, Lower Level\, Hall 4\, Poster 339\nDate/Time: Sunday\, February 27th from 9:45-10:45 AM \nMonday\, February 28\, 2022\nPoster presentation: Unique Epitope for a Natural Human IgE Monoclonal Antibody on Der p 2\nPresenter: Anna Pomés\, PhD FAAAAI\nLocation: Convention Center\, North Building\, Lower Level\, Hall 4\, Poster 659\nDate/Time: Monday\, February 28th from 9:45-10:45 AM \nPoster presentation: Evolution and functional significance of cat allergen\, Fel d 1\nPresenter: Nicole Brackett\, PhD\nLocation: Convention Center\, North Building\, Lower Level\, Hall 4. Poster 656\nDate/Time: Monday\, February 28th from 9:45-10:45 AM \n 
URL:https://inbio.com/event/inbio-attending-aaaai-annual-meeting-2022/
CATEGORIES:Conference
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211208T110000
DTEND;TZID=America/New_York:20211208T120000
DTSTAMP:20260601T230745
CREATED:20221108T150332Z
LAST-MODIFIED:20221108T153451Z
UID:534-1638961200-1638964800@inbio.com
SUMMARY:CRISPR Cat Webinar
DESCRIPTION:Gene Editing of the Major Cat Allergen\, Fel d 1\nIndoor Biotechnologies is applying CRISPR gene editing to delete Fel d 1 from cat cells\, an approach to creating a hypoallergenic cat. Join Indoor Biotechnologies scientists to discuss details of the CRISPR Cat project on the holiday edition of our webinar series on Wednesday\, December 8th at 11am EST. \nIndoor Biotechnologies scientists are investigating the role of Fel d 1 across all cats\, both domesticated and wild. Fel d 1 is the cat allergen of choice as it accounts for 60-90% of anti-cat IgE. Significant research has been conducted at Indoor Biotechnologies to identify conserved regions of the Fel d 1 genes and to delete Fel d 1 from feline cells using CRISPR as an approach that could ultimately be used to generate Fel d 1-free cats.\nThe webinar will cover CRISPR Cat in detail\, providing the origins\, technical background\, data\, and future goals of the project. \nLearning Objectives:\n\nLearn more on the history of CRISPR Cat\, including how the gene for Fel d 1 was first isolated.\nLearn more about CRISPR Cat milestones to date\, including the development\, methods\, and results.\nUnderstand the importance of CRISPR Cat\, and how the project may have larger implications on the application of CRISPR technology in allergy.
URL:https://inbio.com/event/crispr-cat-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211027T110000
DTEND;TZID=America/New_York:20211027T120000
DTSTAMP:20260601T230745
CREATED:20221108T150031Z
LAST-MODIFIED:20221108T153413Z
UID:533-1635332400-1635336000@inbio.com
SUMMARY:SARS-CoV-2 Proteins and Simple T Cell Test Webinar
DESCRIPTION:SARS-CoV-2 Proteins and Simple T cell Test: Essential Tools for COVID-19 Research and Development\nIndoor Biotechnologies has a suite of SARS-CoV-2 proteins in various expression systems\, as well as a rapid whole blood T cell test in development. Join Indoor Biotechnologies scientists to discuss details of these products and technologies on our latest webinar on Wednesday\, October 27th at 11am EDT. \nIndoor Biotechnologies has used its proven expertise in structural biology\, protein expression and purification to manufacture a suite of recombinant SARS-CoV-2 proteins\, including a full-length spike protein. These proteins have been engineered\, optimized and expressed in both mammalian and bacterial expression systems. \nInBio® SARS-CoV-2 proteins are validated for purity by LC-MS/MS\, and their IgG reactivity tested using COVID-19 positive patients’ sera by ELISA. These proteins are manufactured under an ISO 9001:2015 certified Quality Management System. \nIndoor Biotechnologies has developed a rapid whole blood T cell test as part of an Innovate UK grant for assessment of vaccine or viral induced T cell response to SARS-CoV-2. Individuals exposed to SARS-CoV-2 may not produce long-lasting protective antibodies. T cell assays may be an important complement to COVID-19 diagnostic testing and vaccine development. \nInitial trials from InBio® show that the T cell test correlates with PCR and antibody responses and that the test can be used to monitor changes in T cell responses after vaccination. \nPreviously\, virus specific T cell tests have been difficult to standardize and require specific knowledge/equipment\, which presents a significant barrier for large scale\, effective testing. The InBio® simple T cell test aims to break these barriers and is being  optimized for easy implementation\, enabling high throughput testing of COVID-19 T cell immunity. \nThe webinar will cover these products in detail\, providing technical background\, data\, and applications. \nLearning Objectives:\n\nLearn more on the available suite of SARS-CoV-2 proteins\, including ELISA data comparing SARS-CoV-2 nucleocapsid RNA binding domain vs full-length spike proteins in determining vaccine efficiency.\nLearn more about the InBio® simple T cell test\, including the development\, milestones\, and future goals.\nUnderstand how Indoor Biotechnologies’ SARS-CoV-2 resources can aid in COVID-19 research\, diagnostics\, and vaccine efforts.
URL:https://inbio.com/event/sars-cov-2-proteins-and-simple-t-cell-test-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210629T110000
DTEND;TZID=America/New_York:20210629T120000
DTSTAMP:20260601T230745
CREATED:20221108T145517Z
LAST-MODIFIED:20221108T153300Z
UID:532-1624964400-1624968000@inbio.com
SUMMARY:Environmental Testing Suite and Viral Testing Webinar
DESCRIPTION:Environmental Testing Suite and Viral Testing: Use in Product Development and Validation\nIndoor Biotechnologies offers a broad range of product testing services\, including the Environmental Testing Suite and viral testing capabilities in accordance with applicable standards. \nIndoor Biotechnologies has recently expanded facilities and commissioned a new and improved Environmental Testing Suite (ETS) in Cardiff\, Wales. The suite is primarily used to test the safety and efficacy of home and personal care products including air purification devices\, cleaning products\, vacuum cleaners\, carpets and textiles. The facility supports all stages of product development\, from R&D\, to formulation testing and validation of end-product claims. Comprehensive allergen testing is provided onsite. \nAdditionally\, Indoor Biotechnologies offers viral testing services\, including virucidal activity and assessments of virus viability on surfaces and in suspension. Custom testing methods can be designed to test a variety of products for virucidal efficacy\, including Vaccinia virus and Human Coronavirus 229E which can support product claims against coronaviruses\, including SARS-CoV-2. Indoor Biotechnologies laboratories in the UK have tissue culture facilities that operate under Biosafety Level 2 and are ISO 17025 compliant. Utilizing the unique setup of the ETS\, Indoor Biotechnologies are also developing models for viral aerosol studies\, which can be customized to test the safety and efficacy of a range of anti-viral products against airborne viruses. \nLearning Objectives:\n\nLearn more about the ETS and its technical specifications.\nLearn more on Indoor Biotechnologies’ expertise in viral immunology and testing capabilities.\nUnderstand how the ETS and viral testing can help develop\, improve\, and validate products.
URL:https://inbio.com/event/environmental-testing-suite-and-viral-testing-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210421T110000
DTEND;TZID=America/New_York:20210421T120000
DTSTAMP:20260601T230745
CREATED:20221108T145117Z
LAST-MODIFIED:20221108T153104Z
UID:530-1619002800-1619006400@inbio.com
SUMMARY:Molecular Approach to Allergy Diagnostics Webinar
DESCRIPTION:Molecular Approach to Allergy Diagnostics: Innovative Products and Services\nIndoor Biotechnologies has served the allergy diagnostic industry for over 10 years. Using our proven expertise in structural biology and protein expression\, Indoor Biotechnologies has designed and created a comprehensive portfolio of allergen components for diagnostic use\, including dust mite\, animal\, food\, mold\, pollen\, cockroach\, venom and other allergens. \nIn addition\, Indoor Biotechnologies has recently licensed a unique portfolio of Human IgE Monoclonal Antibodies to a diverse panel of clinically important allergens. This technological breakthrough is poised to make a significant impact on diagnostic applications. The human IgE monoclonal antibodies are derived from patients with a clinical history of allergic disease and an excellent alternative to allergic-sera for diagnostic purposes. \nLearning Objectives:\n\nUnderstand the manufacturing and quality benefits of Indoor Biotechnologies’ purified allergens.\nUnderstand the science behind the unique and exclusive Human IgE mAb and the significant impact that they can have in allergy diagnostics.\nUnderstand how Indoor Biotechnologies’ molecular approach to allergy diagnostics can improve new and existing diagnostic platforms.
URL:https://inbio.com/event/molecular-approach-to-allergy-diagnostics-webinar/
CATEGORIES:Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210303T110000
DTEND;TZID=America/New_York:20210303T120000
DTSTAMP:20260601T230745
CREATED:20210224T205845Z
LAST-MODIFIED:20221108T153146Z
UID:392-1614769200-1614772800@inbio.com
SUMMARY:Allergen Variability in Early Introduction Foods Webinar
DESCRIPTION:Allergen Variability in Early Introduction Foods: What Have We Learned?\nInBio has completed a study comparing the allergen content of early introduction food (EIF) brands. This study demonstrated significant variability in the allergen concentration and dose in EIF from 9 manufacturers\, when tested for 17 major allergens. \nTopic:\nUse of MARIA® for Foods to Compare the Allergen Content of Early Introduction Food (EIF) Brands \nDescription:\nInBio’s has further developed its multiplex technology\, MARIA® for Foods\, to simultaneously measure up to 17 major food allergens from a single sample. This state-of-the-art technology was recently used to compare specific food allergen levels in EIF brands\, as reported at the AAAAI annual meeting. The study demonstrated significant variability in the allergen concentration and dose in EIF from nine manufacturers\, when tested for 17 major allergens. \nLearning Objectives:\n\nUnderstand the applications of MARIA® for Foods for measuring specific food allergens\nDiscuss details\, data\, and impact of the EIF study\nUnderstand how Indoor Biotechnologies’ molecular approach to food allergy can improve the quality of EIF and other therapeutic products for food allergy\n\nWho Should Attend:\nAllergists\, Pediatricians\, Health Care Providers\, Food Advocacy and Food Safety Organizations\, Food Industries\, Food Immunotherapy and Diagnostic Companies\, Food Allergen Researchers\, Regulatory Authorities\, Investors\, Consumers and Food Allergy Sufferers.
URL:https://inbio.com/event/allergen-variability-in-early-introduction-foods-webinar/
CATEGORIES:Webinar
END:VEVENT
END:VCALENDAR